ASCO 2021 Updates on De-Escalation Strategies in BC: Talazoparib for gBRCA1/2 Operable TNBC, Neoadjuvant Trastuzumab & Pertuzumab +/- Paclitaxel for HER2+/HR− EBC
Comments 0
Login to view comments.
Click here to Login